Tokyo, Nov. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063676) titled 'Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment' on Nov. 20.
Study Type:
Observational
Primary Sponsor:
Institute - Ferring Pharmaceuticals Co., Ltd.
Condition:
Condition - Non-Muscle-Invasive Bladder Cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To quantify patient preferences for the efficacy, safety, and administration attributes of bladder-sparing therapies for NMIBC.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not a...